Cooper, A. F., Jackson, G., Weinman, J., & Horne, R. (2002). Factors associated with cardiac rehabilitation attendance: A systematic review of the literature. Clinical Rehabilitation, 16, 541-552.
2.
Euroaspire II Study Group. (2001). Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. European Heart Journal, 22, 554-572.
3.
Eyre, H., Kahn, R., Robertson, R. M., Clark, N. G., Doyle, C., Hong, Y., et al. (2004). Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Circulation, 109, 3244-3255.
4.
International Heart Health Society. (2004). The Milan declaration: Positioning technology to serve global heart health.Vancouver, Canada: Author.
5.
Pawson, R., & Tilley, N. (1997). Realistic evaluation. London: Sage.
6.
Pearson, T., Blair, S., Daniels, S., Eckel, R., Fair, J., Fortmann, S., et al. (2000). AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation, 106, 388-402.
7.
Stafford, R., & Radley, D. C. (2003). The underutilization of cardiac medications of proven benefit, 1990 to 2002. Journal of American College of Cardiology, 41(1), 56-61.
8.
World Health Organisation. (2003). Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: Author.
9.
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., & Lanas, F. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet, 364, 937-952.
